It’s only fair to share… Vepdegestrant CAS 2229711-08-2 MW 723.9 g/mol, C45H49N5O4 (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione 5/1/2026, FDA 2026, APROVALS 2026, Veppanu, ARV 471, WC1U3R1YMI, PF 07850327 To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy On May 1, 2026, the …
Category «APPROVALS 2026»
Navepegritide
It’s only fair to share… Navepegritide Cas 2413551-27-4 Molecular Formula: C₂₃₁H₃₈₆N₆₄O₆₇S₅ + (C₂H₄O)₄ₙ (approx. 45 kDa), 1804.0 g/mol MOLECULAR FORMULA C231H386N64O67S5 + (C2H4O)4nMOLECULAR WEIGHT approx. 45 kDa The structure of navepegritide (YUVIWEL®) is built using a “prodrug” design. It is not a simple small molecule, but rather a complex conjugate consisting of three distinct components designed to release the active …
Milsaperidone
It’s only fair to share… Milsaperidone CAS 501373-88-2 C24H29FN2O4 MW 428.50 FDA APPROVED 2/20/2026, Bysanti, To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol 7SV1ZOG031, P-88-8991, (-)-, (S)-Hydroxy Iloperidone, P-88, VHX 869, VHX-896 Milsaperidone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name VHX-896 and …
Copper histidinate
It’s only fair to share… Copper histidinate CAS 12561-67-0 AND 13870-80-9 MF C12H16CuN6O4 FDA 2026, JAN/12/26, Zycubo, To treat Menkes disease, APPROVALS 2026, 9078K3MO9U, MN 88, CUTX 101 copper bis((2S)-2-amino-3-(1H-imidazol-5-yl)propanoate) Copper histidinate, sold under the brand name Zycubo, is a medication used for the treatment of Menkes disease.[1] Copper histidinate is a copper replacement therapy given by subcutaneous injection.[1][2] …
Difamilast
It’s only fair to share… Difamilast FDA 2026, APPROVALS 2026, difamilast, Adquey, 2/12/2026, To treat mild to moderate atopic dermatitis PMDA Moizerto, JAPAN APPROVED 2021/9/27 ジファミラスト ディファミラスト; 地法米司特 N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3- oxazol-4-yl}methyl)-2-ethoxybenzamide OPA-15406 Formula C23H24F2N2O5 CAS 937782-05-3 Mol weight 446.4439 MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406 Efficacy Anti-inflammatory, Phosphodiesterase IV inhibitor Comment Treatment of atopic dermatitis OriginatorOtsuka Pharmaceutical Development …
Islatravir (MK-8591, EFdA)
It’s only fair to share… Islatravir (MK-8591, EFdA) 2′-Deoxy-4′-ethynyl-2-fluoroadenosine Molecular FormulaC12H12FN5O3 Average mass293.254 Da 865363-93-5 2′-Deoxy-4′-ethynyl-2-fluoroadenosine 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Adenosine, 2′-deoxy-4′-C-ethynyl-2-fluoro- (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol 2′-deoxy-4′-c-ethynyl-2-fluoroadenosine 865363-93-5 [RN] 9H-Purin-6-amine, 9-(2-deoxy-4-C-ethynyl-β-D-erythro-pentofuranosyl)-2-fluoro- E2FDA (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol MK-8591 UNII:QPQ082R25D FDA APPROVED 2026, 4/20/2026, doravirine and islatravir, Idvynso To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who …